These results have been confirmed in the phase II CITYSCAPE study, which randomized chemotherapy-naive stage IV NSCLC patients with a PD-L1 TPS ≥1% to receive atezolizumab plus tiragolumab or a placebo. The gene discussed is CD274; the disease is non-small cell lung carcinoma.